GSK plc 6-K/A, filed Feb 3, 2020
GSK plc (GSK)
6-K/A
2020-02-03
For: 2020-02-03
View Original
Added on
August 22, 2026
About this 6-K/A
GSK plc filed this 6-K/A on February 3, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February, 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
GSK publishes provisional dividend dates
|
|
Results
announcement
date
|
Ex-dividend
date
|
Record date
|
Last date for
DRIP elections
|
Payment date
|
|
Q1 2020
|
Wednesday
29
April
|
Thursday
14
May
|
Friday
15
May
|
Thursday
18
June
|
Thursday
9
July
|
|
Q2 2020
|
Wednesday
29
July
|
Thursday
13
August
|
Friday
14
August
|
Thursday
17
September
|
Thursday
8
October
|
|
Q3 2020
|
Wednesday
28
October
|
Thursday
12
November
|
Friday
13
November
|
Monday
21
December
|
Thursday
14
January 2021
|
|
Q4 2020
(Final)
|
Wednesday
3
February 2021
|
Thursday
18
February 2021
|
Friday
19
February 2021
|
Tuesday
16
March 2021
|
Thursday
8 April
2021
|
Company Secretary
3
February 2020
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
03, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|